1. Scrip

Vir Advances HBV, Flu Programs While Focused On COVID-19

Company Brought In Significant Cash Before And After Its IPO

 
• By Mandy Jackson

Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.

Hepatitis B
Vir has multiple COVID-19 programs, but its lead asset is for hepatitis B • Source: Shutterstock

Vir Biotechnology Inc. launched an initial public offering in October to keep progressing its immunological approaches to infectious diseases, including two clinical programs to treat hepatitis B virus (HBV) and prevent influenza A, and preclinical programs in HBV and HIV. Then the COVID-19 pandemic hit and the company’s stock price surged as it put forward multiple programs and entered into partnerships to prevent and treat the novel coronavirus.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas